Pharmacovigilance measures update during & post COVID 19


1st June 2020, 6:30 ( UAE) / 5:30 (KSA & Jordan) / 4:40 (Egypt)

In Collaboration with:

All countries across the world are facing the same challenge: how to ensure the continued availability of medicines for the patients during the COVID-19 pandemic while maintaining high standards of medication safety.
We have invited MENA region pharmacovigilance experts to speak about the

  • Latest updates in PV measures and new requirements
  • Quality challenges for safety reporting activities due to the COVID-19 pandemic
  • Importance of electronic reporting to ensure data exchange for patient safety


Dr. Hadir Rostom

ISoP Egypt Chapter

Dr. Jaber Mohammad

Head of pharmacovigilance section
Jordan Food and Drug Administration

Dr. Houda Sefiani

Medical Doctor
National Pharmacovigilance Centre Morocco ,WHO Collaborating Centre

Dr. Fawaz Alharbi

Director of Drug Safety and Risk Management Department
Saudi Food & Drug Authority

Dr. Brian Edwards

MD MRCP, Principal Consultant
Pharmacovigilance & Drug Safety, NDA Regulatory Science, UK